CENTESSA PHARMACEUTICALS PLC CNTA 深 沪
已收盘 10-31 16:00:00 美东时间
24.90
+0.570
+2.34%
华盛通- 最 高25.13
- 今 开24.44
- 成交量 59.82万股
- 最 低 23.96
- 昨 收 24.33
- 总市值 33.37亿
- 52周最高 25.31
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 9.60
- 委 比 -98.75%
- 总股本 1.34亿
- 历史最高 26.90
- 量 比 0.82
- 振 幅 4.81%
- 历史最低 2.885
- 每 手 1
- 风险率 3.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
华尔街顶级分析师最新评级报告：华纳兄弟探索频道获上调评级
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总如下。以下是由 The Fly 整理的今日投资者需重点关注的评级动态。 五大评级上调案例： 阿格斯...
10-28 22:11
Stephens & Co. Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $35
Stephens & Co. analyst Sudan Loganathan initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating and announces Price Target of $35.
10-28 18:10
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
10-21 05:08
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
Guggenheim Reiterates Buy on Centessa Pharmaceuticals, Maintains $28 Price Target
Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $28 price target.
10-06 21:14
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.
09-12 17:27
Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Centessa Pharmaceuticals plc announced that its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. A fireside chat is scheduled for September 9th at 4:50 PM ET. The event will be available via live audio webcast and archived recording on the company's investor relations website. Centessa focuses on discovering and developing transformational medicines for patients, particularly through its...
09-03 11:00
Centessa rated Outperform at Oppenheimer on ORX750 potential
Centessa Pharmaceuticals (NASDAQ:CNTA) has been rated as Outperform at Oppenheimer, reflecting strong conviction in the company's lead asset, ORX750, an orexin-2 receptor agonist. This upgrade comes a...
08-30 02:53
Centessa Pharmaceuticals Advances Orexin Agonist Pipeline
Centessa Pharmaceuticals Plc ( ($CNTA) ) has released its Q2 earnings. Here is ...
08-13 12:22
